Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013)
Fate Therapeutics' (FATE) quarterly Preferred Stock Liabilities came in at $56.5 million in Q3 2013, little changed on a QoQ basis from $56.5 million in Q4 2012.
Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Fate Therapeutics (FATE) has 2 years of Preferred Stock Liabilities data on file, last reported at $56.5 million in Q3 2013.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $56.5 million in Q3 2013, while the trailing twelve-month figure through Sep 2013 was $56.5 million (changed N/A YoY) and the FY2012 annual result came in at $56.5 million, up 12.36% from the prior year.
- Preferred Stock Liabilities was little changed at $56.5 million in Q3 2013, from $56.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $56.5 million in Q4 2012 to a low of $56.5 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 56.53 Mn |
| Dec 31, 2012 | 56.53 Mn |